Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions.

about

Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions.

Item

http://www.wikidata.org/entity/Q52673331

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Glucose-Lowering Therapies and ...... l Data, and Future Directions.

@en

Glucose-Lowering Therapies and ...... l Data, and Future Directions.

@nl

type

Item

label

Glucose-Lowering Therapies and ...... l Data, and Future Directions.

@en

Glucose-Lowering Therapies and ...... l Data, and Future Directions.

@nl

prefLabel

Glucose-Lowering Therapies and ...... l Data, and Future Directions.

@en

Glucose-Lowering Therapies and ...... l Data, and Future Directions.

@nl

P1476

Glucose-Lowering Therapies and ...... l Data, and Future Directions.

@en

P2093

Muthiah Vaduganathan

http://www.w3.org/2001/XMLSchema#string

Shilpa Vijayakumar

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Metformin activates AMP kinase through inhibition of AMP deaminase

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Influence of diabetes mellitus on heart failure risk and outcome

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.

P304

1060-1073

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.117.032099

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

137

http://www.w3.org/2001/XMLSchema#string

P50

Javed Butler

P577

2018-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29506996

http://www.w3.org/2001/XMLSchema#string

P921

heart failure

type-2 diabetes

P932

5842812

http://www.w3.org/2001/XMLSchema#string